Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.

Abstract

Natalizumab is a humanized monoclonal antibody against alpha4 integrin. In preclinical and clinical studies, natalizumab, which interferes with leukocyte trafficking in the intestinal tract, demonstrated effectiveness in inducing clinical response and maintaining remission in patients with moderate-to-severely active Crohn's disease. However, during… (More)
DOI: 10.1586/17474124.1.1.29

Topics

4 Figures and Tables

Slides referencing similar topics